Jack Pasini

Director/Board Member at Oligomerix, Inc.

Consumer Services

Retail Trade

Health Technology

Profile

Jack Pasini is currently the Director & Chief Commercial Officer at Oligomerix, Inc. He previously worked as the Vice President-Infectious Diseases & Allergy at Pfizer Inc. Mr. Pasini holds an MBA from Fairleigh Dickinson University and an undergraduate degree from Merrimack College.

Jack Pasini active positions

Companies	Position	Start
Oligomerix, Inc. Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY.	Director/Board Member	17/10/2010

All active positions of Jack Pasini

Former positions of Jack Pasini

Companies	Position	End
PFIZER, INC.	Corporate Officer/Principal	-

See the detail of Jack Pasini's experience

Training of Jack Pasini

Merrimack College	Undergraduate Degree
Fairleigh Dickinson University	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jack Pasini's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
PFIZER, INC.	Health Technology

Private companies	1
Oligomerix, Inc. Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY.	Retail Trade